Non-inferiority study comparing Zanubrutinib vs. Bendamustine

Back View

SLIDE KIT 1 06/2020

View

Non-inferiority study comparing Zanubrutinib + Rituximab vs. Bendamustine + Rituximab as 1L treatment in MCL

Rating

Rate this resource

Back

Recent developments
Stay up to date on developments in cancer treatment and subscribe to our newsletter.

Welcome to the BeiGene EU Medical Information Website
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

I am an EU Healthcare Professional from:

You are now leaving the website of BeiGene EU.

You have selected a reference (hyperlink) that leads to an external website. You are leaving the internet pages of BeiGene EU. BeiGene EU is not responsible for the content of websites that can be reached by activating a hyperlink.

Do you really want to leave the website of BeiGene EU?

You are now leaving the italian website of BeiGene EU.

You are now leaving the italian website of BeiGene EU.

Nice to see you!
For newest details on our ESMO materials in a personal video meeting, please click here!

Meet now

Beigenemedical.eu

Virtual Congress

About us

Our compounds

Lifirafenib
Pamiparib
Tislelizumab
Zanubrutinib

Resources

PDF documents

Videos

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.
© 2021 BeiGene. All Rights Reserved. | Privacy Policy | Terms of use | Imprint

Non-inferiority study comparing Zanubrutinib vs. Bendamustine

Rating

Rate this resource

Related resources

Recent developments

Nice to see you!